|
Market Closed -
Nasdaq Stockholm
13:00:00 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 50.40 SEK | -1.18% |
|
-1.18% | -55.87% |
| 10-21 | Devyser wins Italian tender worth SEK 5.7m | FW |
| 10-21 | Devyser Diagnostics AB Wins Tender from Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico Worth Approximately SEK 5.7 Million | CI |
Company Valuation: Devyser Diagnostics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,346 | 1,152 | 1,280 | 1,956 | 1,902 | 851.2 | - | - |
| Change | - | -14.36% | 11.06% | 52.85% | -2.79% | -55.24% | - | - |
| Enterprise Value (EV) 1 | 981 | 810.1 | 1,092 | 1,871 | 1,825 | 804.3 | 812.2 | 796.5 |
| Change | - | -17.42% | 34.78% | 71.38% | -2.48% | -55.92% | 0.98% | -1.93% |
| P/E | -49.6x | -24.7x | -23.9x | -31x | -219x | 86.7x | 26.1x | 14.6x |
| PBR | 3.37x | 2.66x | 3.35x | 5.48x | 5.26x | 2.22x | 2.04x | 1.79x |
| PEG | - | -0.5x | -1.8x | -2.4x | 2.6x | -0x | 0x | 0.2x |
| Capitalization / Revenue | 14.4x | 9.1x | 7.56x | 9.02x | 7.59x | 3.46x | 2.85x | 2.37x |
| EV / Revenue | 10.5x | 6.4x | 6.45x | 8.63x | 7.28x | 3.27x | 2.72x | 2.21x |
| EV / EBITDA | -64.5x | -18.7x | -23.8x | -61.1x | 57.9x | 19.4x | 11.4x | 7.54x |
| EV / EBIT | -46.3x | -15.6x | -18.5x | -32.1x | 181x | 80.6x | 20.2x | 10.9x |
| EV / FCF | -53x | -12.6x | -10.7x | -15.1x | -29.2x | -35x | -47.8x | 159x |
| FCF Yield | -1.89% | -7.95% | -9.32% | -6.61% | -3.43% | -2.86% | -2.09% | 0.63% |
| Dividend per Share 3 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 3 | -1.297 | -1.949 | -2.205 | -2.487 | -0.3609 | 0.3905 | 1.296 | 2.31 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 93.5 | 126.6 | 169.3 | 216.9 | 250.5 | 245.7 | 298.6 | 359.7 |
| EBITDA 1 | -15.2 | -43.4 | -45.8 | -30.6 | 31.5 | 41.43 | 71.17 | 105.7 |
| EBIT 1 | -21.2 | -52 | -58.9 | -58.3 | 10.1 | 9.982 | 40.27 | 73.16 |
| Net income 1 | -20.7 | -46 | -53.6 | -61.5 | -8.4 | 9.78 | 32.34 | 57.55 |
| Net Debt 1 | -364.7 | -342.4 | -188.2 | -85.4 | -77.2 | -46.95 | -39.06 | -54.74 |
| Reference price 3 | 64.32 | 48.07 | 52.70 | 77.09 | 78.89 | 33.84 | 33.84 | 33.84 |
| Nbr of stocks (in thousands) | 15,188 | 16,006 | 16,284 | 16,510 | 16,654 | 16,890 | - | - |
| Announcement Date | 2/24/22 | 2/21/23 | 2/20/24 | 2/13/25 | 2/12/26 | - | - | - |
1DKK in Million2SEK in Million3DKK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 87.81x | 3.31x | 19.66x | -.--% | 85.51M | |
| 18.07x | 6.54x | 12.9x | 1.78% | 65.28B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.57B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.59B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.03B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.17B | |
| -19.41x | 187.75x | -20.66x | -.--% | 39.42B | |
| 28.28x | 8.04x | 20.81x | 0.38% | 32.71B | |
| 27.67x | 5.83x | 15.12x | -.--% | 24.01B | |
| 32.59x | 5.97x | 20.28x | -.--% | 26.5B | |
| Average | 32.73x | 24.12x | 16.02x | 0.31% | 38.34B | |
| Weighted average by Cap. | 26.58x | 24.97x | 15.87x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DVYSR Stock
- Valuation Devyser Diagnostics AB
Select your edition
All financial news and data tailored to specific country editions
